Roche gets exclusive global rights for allogeneic CAR-T cell therapy products incl. P-BCMA-ALLO1 & P-CD19CD20-ALLO1 (Tier 1 program) & options for P-BCMACD19-ALLO1 & P-CD70-ALLO1 (Tier 2 program); exclusive license for allogeneic CAR-T cell therapy products from ~6 collaboration programs (designated by Roche) & option for a non-exclusive, commercial license for ~3 solid tumor targets (licensed products)
If, Roche exercises its option for the Tier 2 program, Poseida will receive an option exercise fee. Before transferring the technology to Roche, Poseida will lead the manufacturing activities (Tier 1 & 2 programs)
Poseida to receive $110M up front, ~ $110M in near-term milestones & is eligible to receive reimbursements, fees & milestones of ~$6.0B incl. ~$1.5B & $1.1B for Tier 1 & 2 programs; $2.9B & $415.0M for the collaboration programs & licensed products along with royalty from the Tier 1 & 2 programs, collaboration programs & for licensed products
Ref: PR Newswire | Image: Poseida Therapeutics
